Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Conditions
Interventions
Ramucirumab (IMC-1211B) DP
Placebo
+1 more
Locations
167
United States
ImClone Investigational Site
Burbank, California, United States
ImClone Investigational Site
Los Angeles, California, United States
ImClone Investigational Site
San Francisco, California, United States
ImClone Investigational Site
Jacksonville, Florida, United States
ImClone Investigational Site
Miramar, Florida, United States
ImClone Investigational Site
Atlanta, Georgia, United States
Start Date
December 1, 2010
Primary Completion Date
July 1, 2013
Completion Date
February 1, 2017
Last Updated
September 18, 2019
NCT04550494
NCT04704661
NCT05489211
NCT05702229
NCT04674267
NCT07217704
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions